Helius Medical Technologies, Inc. (HSDT: OTCQB) | HELIUS MEDICAL TECHNOLOGIES ANNOUNCES ALLOWANCES OF 10 NEW PATENTS

OTC

HELIUS MEDICAL TECHNOLOGIES ANNOUNCES ALLOWANCES OF 10 NEW PATENTS

Jan 04, 2016

OTC Disclosure News Service

Newton, PA

 

 

HELIUS MEDICAL TECHNOLOGIES
ANNOUNCES ALLOWANCES OF 10 NEW PATENTS

 

(Newtown,
PA) – January 4, 2016 – Helius Medical Technologies, Inc.
(CSE:
HSM; OTCQB: HSDT)
(“Helius”,
or the “Company”), a medical technology company focused on the treatment of neurological symptoms caused by disease or trauma,
announced
today that ten (10) new patent applications (seven US and three Chinese) have
been allowed by the US and Chinese Patent Offices in November and December 2015
building on the already strong patent portfolio of the company. The Company has
a further 33 patents (22 US and 11 international) pending on its technology in
the US and other markets around the world.

The patents listed above are design
and utility patents that will help defend against competitive intrusion into
our market and I want to thank Proskauer Rose for its expertise and passion in
helping us create a robust IP portfolio for the PoNS device,” said CEO Phil
Deschamps.

About the PoNS™

The PoNS™ device is a non-invasive means for delivering
neurostimulation through the tongue. The PoNS™ therapy is currently being
studied in the United States and Canada for the treatment of balance disorder
for subjects with mild to moderate Traumatic Brain Injury (“mTBI”), and in
Canada for the treatment of gait and balance disorder for subjects with MS.

The PoNS™ device is believed to be the first non-invasive
means for delivering neurostimulation through the tongue. Researchers believe
that use of the tongue as a gateway to the brain may be one of the most
natural, non-invasive and direct ways to stimulate the brain. The tongue is
anatomically unique, being richly innervated by thousands of nerve fibers and
interconnected to the brainstem by two major cranial nerves.

About Helius Medical Technologies (HMT)

Helius
Medical Technologies is a medical technology company focused on neurological
wellness. HMT seeks to develop, license and acquire unique and non-invasive
platform technologies that amplify the brain’s ability to heal itself. HMT
intends to file for U.S. Food and Drug Administration clearance for the PoNS™
device. For more information, please visit
www.heliusmedical.com. The contents of this
website are not, and should not be deemed to be, incorporated by reference
herein.

Cautionary Disclaimer Statement:

The
Canadian Securities Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of the content of this news release
.

Forward-looking
statements are often identified by terms such as “will”, “may”, “should”,
“anticipate”, “expects” and similar expressions. All statements other than
statements of historical fact, included in this release are forward-looking
statements that involve risks and uncertainties. There can be no assurance that
such statements will prove to be accurate and actual results and future events
could differ materially from those anticipated in such statements. Important
factors that could cause actual results to differ materially from the Company’s
expectations include the failure to satisfy the conditions of the Canadian
Securities Exchange and other risks detailed from time to time in the filings
made by the Company with securities regulations.

The
reader is cautioned that assumptions used in the preparation of any forward-looking
information may prove to be incorrect. Events or circumstances may cause actual
results to differ materially from those predicted, as a result of numerous
known and unknown risks, uncertainties, and other factors, many of which are
beyond the control of the Company. The reader is cautioned not to place undue
reliance on any forward-looking information. Such information, although
considered reasonable by management at the time of preparation, may prove to be
incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly
qualified by this cautionary statement. The forward-looking statements
contained in this news release are made as of the date of this news release and
the Company will update or revise publicly any of the included forward-looking
statements as expressly required by applicable law.

# # #

Contact:
        

Corporate Contact:
                       
Phil
Deschamps

614-596-2597

                        pdeschamps@heliusmedical.com

Investor Relations:

                        778-588-7144

info@heliusmedical.com

Media Contact:

                        Becky Kern

                        914-772-2310

                        media@heliusmedical.com

Copyright © 2016 OTC Markets. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Leave a Reply